Among these evolved diseases are the MRSA (Methicillin-Resistant Staphylococcus aureus) Infections. Staph Aureus was first treated by methicillin by in just two years, new strains of bacteria resistant to methicillin developed. MRSA infections have already taken thousands of lives all over the world. Just in the United States, almost twenty thousand people die of MRSA infection every year.
In the recent years, however, cases of MRSA mortality dropped and infections themselves has become less rampant compared to past years’ MRSA records. This is due to the active participation of different medical groups and hospitals in providing measures to control infection and by giving better home care measures. MRSA drug treatment has been in constant development to cope up with MRSA’s fast evolution.
In spite of these care measures, Staphylococcus aureus continues to evolve and resist other kinds of antibiotics such as penicillin, oxacillin, and amoxicillin. Some strains of MRSA are also often resistant to tetracycline (Sumycin), erythromycin (E-Mycin, Eryc, Ery-Tab, PCE, Pediazole, Ilosone), and clindamycin (Cleocin). This happens because MRSA, also called a superbug by many, can produce a substance called ß-lactamase which degrades penicillin and destroys its antibacterial ability.
In spite of these care measures, Staphylococcus aureus continues to evolve and resist other kinds of antibiotics such as penicillin, oxacillin, and amoxicillin. Some strains of MRSA are also often resistant to tetracycline (Sumycin), erythromycin (E-Mycin, Eryc, Ery-Tab, PCE, Pediazole, Ilosone), and clindamycin (Cleocin). This happens because MRSA, also called a superbug by many, can produce a substance called ß-lactamase which degrades penicillin and destroys its antibacterial ability.